Thrombosis risk modification in transgenic mice containing the human fibrinogen thrombin-binding γ′ chain sequence

Journal of Thrombosis and Haemostasis

Volumn 7, Issue 1, 2009, Pages 102-110

  Mosesson, Michael W ^a   Cooley, B C ^b   Hernandez, I ^a   Diorio, J P ^c   Weiler, H ^a  

^a BLOOD RESEARCH INSTITUTE   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

^c BAXTER HEALTHCARE CORPORATION   (United States)

Author keywords

Antithrombin; Factor V Leiden; Fibrinogen; Thrombin; Thrombosis

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN; FIBRIN; FIBRINOGEN; HETERODIMER; THROMBIN;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARBOXY TERMINAL SEQUENCE; CHIMERA; CONTROLLED STUDY; DISEASE COURSE; DOWN REGULATION; FEMORAL VEIN; HETEROZYGOSITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DETERMINATION; PROTEIN DOMAIN; RISK ASSESSMENT; RISK FACTOR; THROMBOGENESIS; TRANSGENIC MOUSE; VEIN THROMBOSIS; WILD TYPE;

ANIMALS; BINDING SITES; FACTOR V; FIBRINOGEN; HUMANS; MICE; MICE, TRANSGENIC; PLATELET AGGREGATION INHIBITORS; RECOMBINANT FUSION PROTEINS; RISK; THROMBIN; THROMBOSIS;

EID: 57749203814     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2008.03213.x     Document Type: Article

References (45)

1. Finlayson JS, Mosesson MW. Chromatographic heterogeneity of animal fibrinogens. Biochim Biophys Acta 1964; 82: 415-7.
2. Legrele CD, Wolfenstein-Todel C, Hurbourg Y, Mosesson MW. Evidence for two classes of rat plasma fibrinogen γ chains differing by their COOH-terminal amino acid sequence. Biochem Biophys Res Commun 1982; 105: 521-9.
3. Mosesson MW, Finlayson JS. Subfractions of human fibrinogen: Preparation and analysis. J Lab Clin Med 1963; 62: 663-74.
4. Siebenlist KR, Meh DA, Mosesson MW. Plasma factor XIII binds specifically to fibrinogen molecules containing γ′ chains. Biochemistry 1996; 35: 10448-53.
5. Mosesson MW, Finlayson JS, Umfleet RA. Human fibrinogen heterogeneities. III. Identification of γ chain variants. J Biol Chem 1972; 247: 5223-7.
6. Wolfenstein-Todel C, Mosesson MW. Human plasma fibrinogen heterogeneity: evidence for an extended carboxyl-terminal sequence in a normal gamma chain variant (γ′). Proc Natl Acad Sci USA 1980; 77: 5069-73.
7. Chung DW, Davie EW. γ and γ′ chains of human fibrinogen are produced by alternative mRNA processing. Biochemistry 1984; 23: 4232-6.
8. Wolfenstein-Todel C, Mosesson MW. Carboxy-terminal amino acid sequence of a human fibrinogen γ chain variant (γ′). Biochemistry 1981; 20: 6146-9.
9. Meh DA, Siebenlist KR, Mosesson MW. Identification and characterization of the thrombin binding sites on fibrin. J Biol Chem 1996; 271: 23121-5.
10. Meh DA, Mosesson MW, Siebenlist KR, Simpson-Haidaris PJ, Brennan SO, DiOrio JP, Thompson K, Di Minno G. Fibrinogen Naples I (Bβ A68T) non-substrate thrombin binding capacities. Thromb Res 2001; 103: 63-73.
11. Mosesson MW. Update on antithrombin I (fibrin). Thromb Haemost 2007; 98: 105-8.
12. Seegers WH, Nieft M, Loomis EC. Note on the adsorption of thrombin on fibrin. Science 1945; 101: 520-1.
13. Koopman J, Haverkate F, Lord ST, Grimbergen J, Mannucci PM. Molecular basis of fibrinogen Naples associated with defective thrombin binding and thrombophilia. Homozygous substitution of B beta 68 Ala->Thr. J Clin Invest 1992; 90: 238-44.
14. Di Minno G, Martinez J, Cirillo F, Cerbon AM, Silver MJ, Colucci M, Margaglione M, Tauro R, Semeraro N, Quattrone A, Mancini M. Role for platelets and thrombin in the juvenile stroke of two siblings with defective thrombin-absorbing capacity of fibrin(ogen). Arterioscler Thromb 1991; 11: 785-96.
15. Uitte de Willige S, de Visser MC, Houwing-Duistermaat JJ, Rosendaal FR, Vos HL, Bertina RM. Genetic variation in the fibrinogen gamma gene increases the risk of deep venous thrombosis by reducing plasma fibrinogen {gamma} 'levels. Blood 2005; 106: 4176-83.
16. Mosesson MW, Hernandez I, Raife TJ, Medved L, Yakovlev S, Simpson-Haidaris PJ, Uitte de Willige S, Bertina RM. Plasma fibrinogen gamma' chain content in the thrombotic microangiopathy syndrome. J Thromb Haemost 2007; 5: 62-9.
17. Dupuy E, Soria C, Molho P, Zini J-M, Rosenstingl S, Laurian C, Bruneval P, Tobelem G. Embolized ischemic lesions of toes in an afibrinogenemic patient: Possible relevance to in vivo circulating thrombin. Thromb Res 2001; 102: 211-9.
18. de Bosch NB, Mosesson MW, Ruiz-Sáez A, Echenagucia M, Rodriguez-Lemoin A. Inhibition of thrombin generation in plasma by fibrin formation (Antithrombin I). Thromb Haemost 2002; 88: 253-8.
19. de Bosch N, Sáez A, Soria C, Soria J, Echenagucia M. Coagulation profile in afibrinogenemia. Thromb Haemost 1997 (Suppl): 625.
20. Korte W, Feldges A. Increased prothrombin activation in a patient with congenital afibrinogenemia is reversible by fibrinogen substitution. Clin Invest 1994; 72: 396-8.
21. Caen J, Faur Y, Inceman S, Chassineux J, Seligmann M, Anagnostopoulos T, Bernard J. Nécrose ischémique bilatérale dans un cas de grande hypofibrinogénémie congénitale. Nouv Rev Fr Hématol 1964; 4: 321-6.
22. Marchal G, Duhamel G, Samama M, Flandrin G. Thrombose massive des vaisseaux d'un membre au cours d'une hypofibrinémie congénitale. Hémostase 1964; 4: 81-9.
23. Nilsson IM, Niléhn J-E, Cronberg S, Nordén G. Hypofibrinogenemia and massive thrombosis. Acta Med Scand 1966; 180: 65-76.
24. Ingram GI, McBrien DJ, Spencer H. Fatal pulmonary embolism in congenital fibrinopenia. Acta Haematol 1966; 35: 56-62.
25. Mackinnon HH, Fekete JF. Congenital afibrinogenemia: Vascular changes and multiple thrombosis induced by fibrinogen infusions and contraceptive medication. Can Med Assoc J 1971; 140: 597-9.
26. Cronin C, Fitzpatrick D, Temperly I. Multiple pulmonary emboli in a patient with afibrinogenaemia. Acta Haematol 1988; 7: 53-4.
27. Drai E, Taillan B, Schneider S, Ferrari E, Bayle J, Dujardin P. Thrombose portale révélatrice d'une afibrinogénémie congénitale. Presse Méd 1992; 21: 1820-1.
28. Chafa O, Chellali T, Sternberg C, Reghis A, Hamladii RM, Fischer AM. Severe hypofibrinogenemia associated with bilateral ischemic necrosis of toes and fingers. Blood Coagul Fibrinolysis 1995; 6: 549-52.
29. Meh DA, Siebenlist KR, Brennan SO, Holyst T, Mosesson MW. The amino acid sequences in fibrin responsible for high affinity thrombin binding. Thromb Haemost 2001; 85: 470-4.
30. Flick MJ, Du X, Witte DP, Jirouskova M, Soloviev DA, Busittil SJ, Plow EF, Degen JL. Leukocyte engagement of fibrin(ogen) via the integrin receptor alphaMbeta2/Mac-1 is critical for host inflammatory response in vivo. J Clin Invest 2004; 113: 1596-606.
31. Lakso M, Pichel JG, Gorman JR, Sauer B, Okamoto Y, Lee E, Alt FW, Westphal H. Efficient in vivo manipulation of mouse genomic sequences at the zygote stage. Proc Natl Acad Sci U S A 1996; 93: 5860-5.
32. Cui J, Eitzman DT, Westrick RJ, Christie PD, Xu ZJ, Yang AY, Purkayastha AA, Yang TL, Metz AL, Gallagher KP, Tyson JA, Rosenberg RD, Ginsburg D. Spontaneous thrombosis in mice carrying the factor V leiden mutation. Blood 2000; 96: 4222-6.
33. Laki K. The polymerization of proteins: The action of thrombin on fibrinogen. Arch Biochem Biophys 1951; 32: 317-24.
34. Mosesson MW, Sherry S. The preparation and properties of human fibrinogen of relatively high solubility. Biochemistry 1966; 5: 2829-35.
35. Lorand L, Gotoh T. Fibrinoligase. The fibrin stabilizing factor Methods Enzymol 1970; 19: 770-82.
36. Loewy AG, Dunathan K, Kriel R, Wolfinger HL. Fibrinase I. Purification of substrate and enzyme. J Biol Chem 1961; 236: 2625-33.
37. Jirouskova M, Smyth SS, Kudryk B, Coller BS. A hamster antibody to the mouse fibrinogen gamma chain inhibits platelet-fibrinogen interactions and FXIIIa-mediated fibrin cross-linking, and facilitates thrombolysis. Thromb Haemost 2001; 86: 1047-56.
38. Siebenlist KR, Mosesson MW, Hernandez I, Bush LA, Di Cera E, Shainoff JR, DiOrio JP, Stojanovich L. Studies on the basis for the properties of fibrin produced from fibrinogen containing γ′ chains. Blood 2005; 106: 2730-6.
39. Cooley BC, Szema L, Chen C-Y, Schwab JP, Schmeling G. A murine model of deep vein thrombosis. Characterization and validation in transgenic mice. Thromb Haemost 2005; 94: 498-503.
40. Siebenlist KR, Meh D, Mosesson MW. Protransglutaminase (factor XIII) mediated crosslinking of fibrinogen and fibrin. Thromb Haemost 2001; 86: 1221-8.
41. Kirschbaum NE, Mosesson MW, Amrani DL. Characterization of the γ chain platelet binding site on fibrinogen fragment D. Blood 1992; 79: 2643-8.
42. Mosesson MW. Antithrombin I. Inhibition of thrombin generation in plasma by fibrin formation. Thromb Haemost 2003; 89: 9-12.
43. Cheung EY, Uitte de WS, Vos HL, Leebeek FW, Dippel DW, Bertina RM, de Maat MP. Fibrinogen gamma' in ischemic stroke: A case-control study. Stroke 2008; 39: 1033-5.
44. Lovely RS, Falls LA, Al Mondhiry HA, Chambers CE, Sexton GJ, Ni H, Farrell DH. Association of γA/γ′ fibrinogen levels and coronary artery disease. Thromb Haemost 2002; 88: 26-31.
45. Siebenlist KR, Mosesson MW, Meh DA, DiOrio JP, Albrecht RM, Olson JD. Coexisting dysfibrinogenemia (gammaR275C) and factor V Leiden deficiency associated with thromboembolic disease (fibrinogen Cedar Rapids). Blood Coagul Fibrinolysis 2000; 11: 293-304.